PFE tilrekimig phase 2 study meets primary endpoint
Tilrekimig showed statistically significant skin clearance in a phase 2 atopic dermatitis study, meeting its primary endpoint at week 16 across all evaluated doses.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer's AD Drug Tilrekimig Meets Phase 2 Primary Endpoint
Pfizer Inc. (PFE) announced that its investigational trispecific antibody, tilrekimig, met the primary endpoint in a Phase 2 study for atopic dermatitis. The study measured EASI-75 at Week 16 compared to placebo. Phase 3 programs for atopic dermatitis and asthma are currently underway.